Q-omics provides the consensus-scored GOLGA6L6 profile across patient tissues and cancer cell-line models. GOLGA6L6 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GOLGA6L6 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, GOLGA6L6 RNA expression shows 6,271 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, LUSC, and STAD as cancer lineages where GOLGA6L6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA6L6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA6L6 survival associations across molecular data types. GOLGA6L6 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA6L6 RNA expression–survival associations across cancer types. High GOLGA6L6 expression shows unfavorable associations in UVM, ACC, SKCM, DLBC and SCLC, but favorable associations in HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GOLGA6L6 RNA expression.
This table summarizes GOLGA6L6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA6L6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA6L6 shows lower tumor expression in STAD and higher tumor expression in LUSC. The LUSC box plot shows higher GOLGA6L6 RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p = .049).
This table shows molecular features associated with GOLGA6L6 in patient tissues and cancer cell lines. In patient samples, GOLGA6L6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA6L6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
